Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. hemodynamic
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Hemodynamic Articles & Analysis

65 news found

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Mineralocorticoid receptor (MR) overactivation contributes to CKD progression and CV damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. ...

ByBayer AG


Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology

Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology

Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. ...

ByMedicalgorithmics S.A.


Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

” Mineralocorticoid receptor (MR) overactivation contributes to CKD progression and CV damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. ...

ByBayer AG


Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

” Mineralocorticoid receptor (MR) overactivation contributes to CKD progression and CV damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. ...

ByBayer AG


Bodyport Announces Appointment of Jim Pursley to Board of Directors

Bodyport Announces Appointment of Jim Pursley to Board of Directors

About Bodyport Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. ...

ByBodyport Inc.


Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results

Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results

The device’s modular design allows for hemodynamic support through multiple pumps anchored in parallel in the descending aorta. ...

ByPuzzle Medical Devices Inc.


Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure

Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure

” The study titled, “Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients with Worsening Heart Failure,” assessed the relationship between blood volume, resting, and stress cardiovascular pressures in worsening HF. ...

ByDaxor Corporation


Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

MR overactivation contributes to CKD progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Based on the positive results of the FIDELIO-DKD Phase III study, Kerendia was granted marketing authorization by the U.S. ...

ByBayer AG


Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

Patients experienced immediate hemodynamic and symptom improvement with modest hospital resource burden, demonstrated by minimal need for adjunctive therapy and a median post procedure ICU stay of 0 days. ...

ByInari Medical


Puzzle Medical Devices Inc. Wins TCT 2022 Shark Tank Innovation Competition

Puzzle Medical Devices Inc. Wins TCT 2022 Shark Tank Innovation Competition

” The ModulHeart device provides hemodynamic support through three endovascular pumps inserted in series and assembled in parallel into a self-expandable anchor implanted in the descending aorta. ...

ByPuzzle Medical Devices Inc.


Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

MR overactivation contributes to CKD progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. The Phase III study programme with finerenone, FINEOVATE, currently comprises five Phase III studies, FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF, FIND-CKD, and FIONA, as well as the Phase II study CONFIDENCE. ...

ByBayer AG


Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences

Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences

The study evaluates short and long-term clinical outcomes of patients treated with the FlowTriever system, including safety results, on-table hemodynamic improvements, and hospital resource utilization. The data will be presented by Dr. ...

ByInari Medical


Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™

Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™

The device’s modular design allows for hemodynamic support through multiple pumps anchored in parallel in the descending aorta. ...

ByPuzzle Medical Devices Inc.


Bodyport Receives FDA Clearance for the Bodyport Cardiac Scale

Bodyport Receives FDA Clearance for the Bodyport Cardiac Scale

[i] More than 90% of these hospitalizations are due to hemodynamic changes resulting in fluid accumulation.[ii] Weight monitoring is currently the noninvasive standard of care for detecting fluid changes in patients with heart failure. ...

ByBodyport Inc.


Assessing Heart Function and Fluid Status with Cardiac Scales: Interview with John Lipman, CEO, and Corey Centen, Founder, Bodyport

Assessing Heart Function and Fluid Status with Cardiac Scales: Interview with John Lipman, CEO, and Corey Centen, Founder, Bodyport

The device can transmit the data on cardiac hemodynamic parameters to clinicians through cellular networks, and uses AI-based algorithms to identify a variety of hemodynamic biomarkers to aid in early identification and diagnosis. ...

ByBodyport Inc.


Robocath’s joint venture, Cathbot, concludes first clinical study in China to evaluate robotic PCI safety and efficacy

Robocath’s joint venture, Cathbot, concludes first clinical study in China to evaluate robotic PCI safety and efficacy

In the future, R-One will be equipped with 5G and AI features and combined with technologies such as vascular structure imaging and hemodynamic monitoring to achieve more innovative breakthroughs. Our ambition is to provide the best treatment for patients thanks to accurate, intelligent and better integrated robotic solutions,” concluded Dr. ...

ByRobocath


Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

The pumps functioned as expected and provided patients with signi?cant improvement in hemodynamic parameters. I am excited about Puzzle Medical’s progress and the potential for this device to disrupt HF treatment,” said Dr. ...

ByPuzzle Medical Devices Inc.


Kerendia (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes

Kerendia (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes

MR overactivation contributes to CKD progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. The Phase III study programme with finerenone, FINEOVATE, currently comprises five Phase III studies, FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF, FIND-CKD, and FIONA, as well as the Phase II study CONFIDENCE. ...

ByBayer AG


Bodyport Appoints John Lipman as Chief Executive Officer

Bodyport Appoints John Lipman as Chief Executive Officer

” About Bodyport Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. ...

ByBodyport Inc.


V-Wave’s Ventura interatrial shunt: one year follow-up from relieve-HF Roll-in arm shows improved left and right ventricular function in patients with advanced heart failure

V-Wave’s Ventura interatrial shunt: one year follow-up from relieve-HF Roll-in arm shows improved left and right ventricular function in patients with advanced heart failure

“Moreover, this strategy does not to require the additional complexity and cost of performing invasive hemodynamic exercise testing to determine candidacy for shunt placement. ...

ByV-Wave Ltd.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT